Participant Flow



Baseline characteristics

	Colorectal origin	Gynaecological origin	Total
Number	19 (63)	11 (37)	30
Age (years)	38-85	18-84	18-85
Gender			
Female	13 (68)	11 (100)	24 (81)
Male	6 (32)	0	6 (19)
Presentation			
Primary in situ	7 (37)	0	7 (23)
Primary in situ	5 (26)	2 (18)	7 (23)
Peritoneal only	7 (37)	9 (82)	16 (54)
Stage of disease			
Stage 1	0	0	0
Stage 2	0	0	0
Stage 3	6 (32)	7 (64)	12 (40)
Stage 4	12 (63)	4 (36)	16 (54)
Stage unspecified	1 (5)	0	1 (3)
Chemotherapy			
Yes	14 (74)	10 (91)	24 (81)
No	5 (26)	1 (9)	6 (19)
Line of treatment			
1	11 (79)	2 (20)	13 (54)
2	2 (14)	1 (10)	3 (13)
3	0	5 (50)	5 (20)
4	1 (7)	2 (20)	3 (13)
Performance status			
0	9 (47)	4 (36)	13 (43)
1	8 (42)	5 (46)	13 (43)
2	2 (11)	2 (18)	4 (14)
Body Mass Index	19.9 – 44.6	18.7 – 38.3	18.7 - 44.6
Nutritional supplements prescribed			
Yes n (%)	13 (68)	5 (46)	18 (60)

Outcome Measures: Symptoms

		Baseline Day 1	End of trial Day 28	p-value
No completing questionnaire		24	24	
		n (%)	n (%)	
Was pain present?	Yes	23 (96)	15 (63)	p=0.004
How severe was it?	Slight	2 (9)	5 (33)	
	Moderate	13 (57)	6 (40)	
	Severe	7 (30)	3 (20)	
	Very severe	1 (4)	0	
	Missing	0	1 (7)	
Did bloating occur?	Yes	21 (88)	16 (67)	p=0.09
How severe was it?	Slight	2 (10)	4 (25)	
	Moderate	11 (52)	10 (63)	
	Severe	3 (14)	1 (6)	
	Very severe	4 (19)	1 (6)	
	Missing	1 (5)		
Did early satiety occur?	Yes	21 (88)	20 (83)	p=0.68
How severe was it?	Slight	2 (10)	8 (40)	
	Moderate	10 (47)	6 (30)	
	Severe	4 (19)	2 (10)	
	Very severe	4 (19)	2 (10)	
	Missing	1 (5)	2(10)	
Did nausea occur?	Yes	16 (67)	13 (54)	p=0.38
How severe was it?	Slight	5 (31)	5 (38)	
	Moderate	6 (37)	5 (38)	
	Severe	2 (13)	1 (8)	
	Very severe	1 (6)	0	
	Missing	2 (13)	2 (16)	
Did vomiting occur?	Yes	9 (38)	5 (21)	p=0.20
How severe was it?	Slight	2 (22)	2 (40)	
	Moderate	2 (22)	2 (40)	
	Severe	4 (45)	0	
	Very severe	1 (11)	1 (20)	

Outcome measures: Ease of Use questionnaire



Outcome measures: Hospital admissions

Outcome		n	Mean (SD)	p-value (Wilcoxon rank-sum)
Number of admissions	Prior 3 months	23	0.88 (1.2)	0.018
	Prior 28 days	14	0.54 (0.8)	
	Trial period	4	0.15 (0.4)	
Number of bed days	Prior 3 months	82	3.15 (4.7)	0.004
	Prior 28 days	45	1.73 (3.1)	
	Trial period	21	0.81 (2.2)	

Outcome measures: Quality of life

91% (n=21/23): improvement or no change in Global Health status P<0.001



Outcome measures: Anthropometry

	Colorectal origin	Gynaecological origin	Total
Number n (%)	16 (63)	10 (37)	26
% weight change from Day 1–Day 28	-13.1 – 2.3 (-2.9, 3.6)*	-10.5 – 9.5 (-1.8, 5.6)	-13.1 – 9.5 (-2.6, 4.5)
% weight changes between Stage of disease			
Stage 3	-13.1 – 2.3 (-2.8, 5.4)	-10.5 – 1.5 (-2.4, 4.2)	-13.1 – 2.3 (-2.4, 4.5)
Stage 4	-7.8 – 0 (-3.3, 2.4)	-8.6 – 9.5 (-0.3, 9.1)	-8.6 – 9.5 (-2.4, 4.4)
% weight changes between PS scores			
PS 0	-13.1 – 2.3 (-2.7, 4.5)	-4.6 – 9.5 (1.1, 6.1)	-13.1 – 9.5 (-1.3, 5.0)
PS 1	-6.3 – 0.3 (-2.9, 2.3)	-8.6 – 1.5 (-2.3, 4.0)	-8.6 – 1.5 (-2.4, 2.9)
PS 2	-7.8	-10.5	-10.5 - -7.8
Weight change n (% of cohort)			
Weight gain	2 (13)	4 (40)	6 (23)
No weight change	1 (6)	0	1 (4)
< 5% weight loss	10 (62)	4 (40)	14 (54)
5-10% weight loss	2 (13)	1 (10)	3 (12)
>10% weight loss	1 (6)	1 (10)	2 (8)

*Figures in brackets denote (mean, SD)

Adverse events

None reported